497 related articles for article (PubMed ID: 26202045)
1. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Hashida S; Yamamoto H; Shien K; Miyoshi Y; Ohtsuka T; Suzawa K; Watanabe M; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2015 Oct; 106(10):1377-84. PubMed ID: 26202045
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
5. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
Sugano T; Seike M; Noro R; Soeno C; Chiba M; Zou F; Nakamichi S; Nishijima N; Matsumoto M; Miyanaga A; Kubota K; Gemma A
Mol Cancer Ther; 2015 Nov; 14(11):2433-40. PubMed ID: 26351321
[TBL] [Abstract][Full Text] [Related]
7. Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.
Sato H; Shien K; Tomida S; Okayasu K; Suzawa K; Hashida S; Torigoe H; Watanabe M; Yamamoto H; Soh J; Asano H; Tsukuda K; Miyoshi S; Toyooka S
Sci Rep; 2017 Jan; 7():40847. PubMed ID: 28084458
[TBL] [Abstract][Full Text] [Related]
8. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
12. Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors.
Nanjo S; Yamada T; Nishihara H; Takeuchi S; Sano T; Nakagawa T; Ishikawa D; Zhao L; Ebi H; Yasumoto K; Matsumoto K; Yano S
PLoS One; 2013; 8(12):e84700. PubMed ID: 24386407
[TBL] [Abstract][Full Text] [Related]
13. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Coco S; Truini A; Alama A; Dal Bello MG; Venè R; Garuti A; Carminati E; Rijavec E; Genova C; Barletta G; Sini C; Ballestrero A; Boccardo F; Grossi F
Target Oncol; 2015 Sep; 10(3):393-404. PubMed ID: 25341405
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
[TBL] [Abstract][Full Text] [Related]
16. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
[TBL] [Abstract][Full Text] [Related]
17. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
[TBL] [Abstract][Full Text] [Related]
18. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
19. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
